(RTTNews) - Tuesday, CSL Seqirus, a business of CSL (CSL.AX), said it has expanded the availability of influenza vaccines in the U.S. following the successful completion of its 2026/27 manufacturing campaign. The company said most customer orders have already been shipped, with remaining deliveries expected to be completed ahead of schedule. Additional vaccine doses are available to support customers and public health vaccination efforts throughout the influenza season. The update comes amid reported supply challenges in parts of the U.S. and global influenza vaccine market following three WHO-recommended strain changes for the upcoming season.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。